SCHEMBL30765461

SCHEMBL30765461

COc1cccc(-c2ccc(C(=O)O)cc2F)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 5/20 0.64
AKR1C2 P52895 5/20 0.64
CYP2C8 P10632 1/20 0.53
MAPK1 P28482 2/20 0.53
LMNA P02545 1/20 0.53
HTT P42858 1/20 0.53
RAB9A P51151 1/20 0.53
DHODH Q02127 2/20 0.50
ROCK1 Q13464 2/20 0.50
KDM4E B2RXH2 1/20 0.50
RPS6KA5 O75582 1/20 0.50
MAP4K4 O95819 1/20 0.50
PRKCG P05129 1/20 0.50
CDK1 P06493 1/20 0.50
PRKACA P17612 1/20 0.50
RPS6KB1 P23443 1/20 0.50
CDK2 P24941 1/20 0.50
AKT1 P31749 1/20 0.50
AKT2 P31751 1/20 0.50
FLT4 P35916 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31558511 0.87 AKR1C3 (0.60) AKR1C3AKR1C2MAPK1LMNAHTT
SCHEMBL26657585 0.85 PTGS2 (0.67) AKR1C3AKR1C2DHODHRXRAPTGS2
SCHEMBL29793330 0.85 PTGS2 (0.67) AKR1C3AKR1C2DHODHRXRAPTGS2
SCHEMBL22189997 0.84 AKR1C3 (0.56) AKR1C3AKR1C2CYP2C8MAPK1LMNA
SCHEMBL26911126 0.84 CYP2C19 (0.62) AKR1C3AKR1C2CYP2C8MAPK1LMNA
SCHEMBL23484836 0.82 CYP2C19 (0.60) AKR1C3AKR1C2CYP2C8MAPK1LMNA
SCHEMBL2744367 0.81 MAPT (0.54) CYP2C8LMNARAB9AKDM4ERXRA
SCHEMBL29651459 0.81 LMNA (0.62) CYP2C8MAPK1LMNAHTTRAB9A
SCHEMBL1607173 0.81 LMNA (0.62) CYP2C8MAPK1LMNAHTTRAB9A
SCHEMBL29788306 0.81 CYP2C19 (0.58) AKR1C3AKR1C2CYP2C8MAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed